Does the media favor HIMS or NEO?

In the previous week, Hims & Hers Health had 17 more articles in the media than NeoGenomics. MarketBeat recorded 27 mentions for Hims & Hers Health and 10 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.53 beat Hims & Hers Health's score of 0.26 indicating that NeoGenomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 5 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral NeoGenomics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NEO or HNGE?

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 3.19 -$108.03M -$0.40 N/A Hinge Health $720.06M 9.78 -$528.26M $1.28 68.18

Is NEO or HNGE more profitable?

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% Hinge Health 15.15% 51.60% 14.16%

Does the media favor NEO or HNGE?

In the previous week, NeoGenomics had 3 more articles in the media than Hinge Health. MarketBeat recorded 10 mentions for NeoGenomics and 7 mentions for Hinge Health. Hinge Health's average media sentiment score of 0.58 beat NeoGenomics' score of 0.53 indicating that Hinge Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Hinge Health 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, NEO or CHE?

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeoGenomics $727.33M 3.19 -$108.03M -$0.40 N/A Chemed $2.53B 2.70 $265.24M $19.91 26.30

Is NEO or CHE more profitable?

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets NeoGenomics -6.77% -1.99% -1.21% Chemed 10.60% 31.77% 18.90%

Does the media favor NEO or CHE?

In the previous week, Chemed had 9 more articles in the media than NeoGenomics. MarketBeat recorded 19 mentions for Chemed and 10 mentions for NeoGenomics. Chemed's average media sentiment score of 1.17 beat NeoGenomics' score of 0.53 indicating that Chemed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Chemed 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, RDNT or NEO?

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RadNet $2.04B 2.88 -$18.65M -$0.27 N/A NeoGenomics $727.33M 3.19 -$108.03M -$0.40 N/A

Is RDNT or NEO more profitable?

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity. Company Net Margins Return on Equity Return on Assets RadNet -0.93% 2.61% 0.91% NeoGenomics -6.77% -1.99% -1.21%

Does the media refer more to RDNT or NEO?

In the previous week, RadNet had 3 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for RadNet and 10 mentions for NeoGenomics. RadNet's average media sentiment score of 1.60 beat NeoGenomics' score of 0.53 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeoGenomics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NEO or LFST?

In the previous week, NeoGenomics had 3 more articles in the media than LifeStance Health Group. MarketBeat recorded 10 mentions for NeoGenomics and 7 mentions for LifeStance Health Group. LifeStance Health Group's average media sentiment score of 1.07 beat NeoGenomics' score of 0.53 indicating that LifeStance Health Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeoGenomics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive LifeStance Health Group 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

NeoGenomics (NEO) Competitors

$18.05 -0.59 (-3.17%)

As of 08/28/2026 04:00 PM Eastern

Compare

NEO vs. HIMS, HNGE, CHE, RDNT, and LFST

Should you buy NeoGenomics stock or one of its competitors? NeoGenomics's main competitors and comparable companies include Hims & Hers Health (HIMS), Hinge Health (HNGE), Chemed (CHE), RadNet (RDNT), and LifeStance Health Group (LFST). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does NeoGenomics compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 98.5% of NeoGenomics shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 1.1% of NeoGenomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Hims & Hers Health has higher revenue and earnings than NeoGenomics. Hims & Hers Health is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.58B	2.61	$128.37M	-$0.63	N/A
NeoGenomics	$727.33M	3.19	-$108.03M	-$0.40	N/A

Hims & Hers Health currently has a consensus target price of $32.50, suggesting a potential upside of 12.53%. NeoGenomics has a consensus target price of $16.71, suggesting a potential downside of 7.40%. Given Hims & Hers Health's higher probable upside, research analysts plainly believe Hims & Hers Health is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Hims & Hers Health had 17 more articles in the media than NeoGenomics. MarketBeat recorded 27 mentions for Hims & Hers Health and 10 mentions for NeoGenomics. NeoGenomics' average media sentiment score of 0.53 beat Hims & Hers Health's score of 0.26 indicating that NeoGenomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	5 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
NeoGenomics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Hims & Hers Health has a net margin of -5.51% compared to NeoGenomics' net margin of -6.77%. NeoGenomics' return on equity of -1.99% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-5.51%	-6.51%	-1.20%
NeoGenomics	-6.77%	-1.99%	-1.21%

Hims & Hers Health has a beta of 2.4, suggesting that its stock price is 140% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

Summary

NeoGenomics beats Hims & Hers Health on 9 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to Hinge Health?

NeoGenomics (NASDAQ:NEO) and Hinge Health (NYSE:HNGE) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

NeoGenomics has higher revenue and earnings than Hinge Health. NeoGenomics is trading at a lower price-to-earnings ratio than Hinge Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.19	-$108.03M	-$0.40	N/A
Hinge Health	$720.06M	9.78	-$528.26M	$1.28	68.18

NeoGenomics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Hinge Health has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market.

In the previous week, NeoGenomics had 3 more articles in the media than Hinge Health. MarketBeat recorded 10 mentions for NeoGenomics and 7 mentions for Hinge Health. Hinge Health's average media sentiment score of 0.58 beat NeoGenomics' score of 0.53 indicating that Hinge Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Hinge Health	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Hinge Health has a net margin of 15.15% compared to NeoGenomics' net margin of -6.77%. Hinge Health's return on equity of 51.60% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Hinge Health	15.15%	51.60%	14.16%

NeoGenomics currently has a consensus price target of $16.71, suggesting a potential downside of 7.40%. Hinge Health has a consensus price target of $100.57, suggesting a potential upside of 15.24%. Given Hinge Health's stronger consensus rating and higher probable upside, analysts plainly believe Hinge Health is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Hinge Health	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

98.5% of NeoGenomics shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 18.9% of Hinge Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Hinge Health beats NeoGenomics on 11 of the 16 factors compared between the two stocks.

How does NeoGenomics compare to Chemed?

NeoGenomics (NASDAQ:NEO) and Chemed (NYSE:CHE) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Chemed has a net margin of 10.60% compared to NeoGenomics' net margin of -6.77%. Chemed's return on equity of 31.77% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
Chemed	10.60%	31.77%	18.90%

NeoGenomics presently has a consensus target price of $16.71, suggesting a potential downside of 7.40%. Chemed has a consensus target price of $530.75, suggesting a potential upside of 1.37%. Given Chemed's higher possible upside, analysts clearly believe Chemed is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Chemed	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17

98.5% of NeoGenomics shares are held by institutional investors. Comparatively, 95.9% of Chemed shares are held by institutional investors. 1.1% of NeoGenomics shares are held by insiders. Comparatively, 3.3% of Chemed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Chemed has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.19	-$108.03M	-$0.40	N/A
Chemed	$2.53B	2.70	$265.24M	$19.91	26.30

NeoGenomics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Chemed has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

In the previous week, Chemed had 9 more articles in the media than NeoGenomics. MarketBeat recorded 19 mentions for Chemed and 10 mentions for NeoGenomics. Chemed's average media sentiment score of 1.17 beat NeoGenomics' score of 0.53 indicating that Chemed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemed	16 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Chemed beats NeoGenomics on 11 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to RadNet?

RadNet (NASDAQ:RDNT) and NeoGenomics (NASDAQ:NEO) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

RadNet currently has a consensus target price of $90.00, indicating a potential upside of 20.63%. NeoGenomics has a consensus target price of $16.71, indicating a potential downside of 7.40%. Given RadNet's stronger consensus rating and higher possible upside, equities research analysts plainly believe RadNet is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, RadNet had 3 more articles in the media than NeoGenomics. MarketBeat recorded 13 mentions for RadNet and 10 mentions for NeoGenomics. RadNet's average media sentiment score of 1.60 beat NeoGenomics' score of 0.53 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeoGenomics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has higher revenue and earnings than NeoGenomics. RadNet is trading at a lower price-to-earnings ratio than NeoGenomics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.88	-$18.65M	-$0.27	N/A
NeoGenomics	$727.33M	3.19	-$108.03M	-$0.40	N/A

RadNet has a net margin of -0.93% compared to NeoGenomics' net margin of -6.77%. RadNet's return on equity of 2.61% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.93%	2.61%	0.91%
NeoGenomics	-6.77%	-1.99%	-1.21%

RadNet has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, NeoGenomics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

77.9% of RadNet shares are held by institutional investors. Comparatively, 98.5% of NeoGenomics shares are held by institutional investors. 5.1% of RadNet shares are held by insiders. Comparatively, 1.1% of NeoGenomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

RadNet beats NeoGenomics on 12 of the 17 factors compared between the two stocks.

How does NeoGenomics compare to LifeStance Health Group?

NeoGenomics (NASDAQ:NEO) and LifeStance Health Group (NASDAQ:LFST) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

LifeStance Health Group has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than LifeStance Health Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$727.33M	3.19	-$108.03M	-$0.40	N/A
LifeStance Health Group	$1.42B	3.35	$9.66M	$0.13	94.69

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 1.1% of NeoGenomics shares are owned by insiders. Comparatively, 3.5% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

NeoGenomics presently has a consensus price target of $16.71, suggesting a potential downside of 7.40%. LifeStance Health Group has a consensus price target of $12.38, suggesting a potential upside of 0.53%. Given LifeStance Health Group's higher possible upside, analysts plainly believe LifeStance Health Group is more favorable than NeoGenomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
LifeStance Health Group	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, NeoGenomics had 3 more articles in the media than LifeStance Health Group. MarketBeat recorded 10 mentions for NeoGenomics and 7 mentions for LifeStance Health Group. LifeStance Health Group's average media sentiment score of 1.07 beat NeoGenomics' score of 0.53 indicating that LifeStance Health Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
LifeStance Health Group	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

NeoGenomics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, LifeStance Health Group has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

LifeStance Health Group has a net margin of 3.19% compared to NeoGenomics' net margin of -6.77%. LifeStance Health Group's return on equity of 3.39% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-6.77%	-1.99%	-1.21%
LifeStance Health Group	3.19%	3.39%	2.33%

Summary

LifeStance Health Group beats NeoGenomics on 11 of the 15 factors compared between the two stocks.

Get NeoGenomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEO vs. The Competition

Export

Metric	NeoGenomics	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.32B	$9.87B	$7.20B	$12.90B
Dividend Yield	N/A	2.56%	2.54%	11.28%
P/E Ratio	-45.13	34.69	273.16	25.45
Price / Sales	3.19	4.88	604.43	75.83
Price / Cash	53.87	120.59	76.74	53.00
Price / Book	2.95	4.00	12.98	6.14
Net Income	-$108.03M	$312.92M	$3.48B	$348.86M
7 Day Performance	6.30%	-1.34%	0.13%	-0.80%
1 Month Performance	13.66%	0.93%	7.08%	4.13%
1 Year Performance	105.58%	15.34%	24.67%	15.17%

NeoGenomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEO NeoGenomics	1.4761 of 5 stars	$18.05 -3.2%	$16.71 -7.4%	+105.6%	$2.32B	$727.33M	N/A	2,500	News Coverage
HIMS Hims & Hers Health	2.1485 of 5 stars	$31.08 -8.0%	$32.50 +4.6%	-31.8%	$7.88B	$2.35B	N/A	2,442	Trending News
HNGE Hinge Health	4.0541 of 5 stars	$89.79 +1.5%	$100.57 +12.0%	+55.0%	$7.14B	$587.86M	70.15	1,437
CHE Chemed	3.5854 of 5 stars	$540.18 -0.1%	$530.75 -1.7%	+14.2%	$7.07B	$2.53B	27.13	15,811	News Coverage Positive News
RDNT RadNet	4.0895 of 5 stars	$74.69 -2.8%	$88.00 +17.8%	+4.0%	$6.05B	$2.27B	N/A	11,264	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEO) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeoGenomics (NEO) Competitors

NEO vs. HIMS, HNGE, CHE, RDNT, and LFST

How does NeoGenomics compare to Hims & Hers Health?

Summary

How does NeoGenomics compare to Hinge Health?

Summary

How does NeoGenomics compare to Chemed?

Summary

How does NeoGenomics compare to RadNet?

Summary

How does NeoGenomics compare to LifeStance Health Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeoGenomics (NEO) Competitors

NEO vs. HIMS, HNGE, CHE, RDNT, and LFST

How does NeoGenomics compare to Hims & Hers Health?

Do insiders and institutionals hold more shares of HIMS or NEO?

Which has better valuation and earnings, HIMS or NEO?

Do analysts recommend HIMS or NEO?

Does the media favor HIMS or NEO?

Is HIMS or NEO more profitable?

Which has more volatility & risk, HIMS or NEO?

Summary

How does NeoGenomics compare to Hinge Health?

Which has better earnings and valuation, NEO or HNGE?

Which has more risk & volatility, NEO or HNGE?

Does the media favor NEO or HNGE?

Is NEO or HNGE more profitable?

Do analysts rate NEO or HNGE?

Do insiders & institutionals have more ownership in NEO or HNGE?

Summary

How does NeoGenomics compare to Chemed?

Is NEO or CHE more profitable?

Do analysts rate NEO or CHE?

Do insiders and institutionals have more ownership in NEO or CHE?

Which has higher valuation and earnings, NEO or CHE?

Which has more risk and volatility, NEO or CHE?

Does the media favor NEO or CHE?

Summary

How does NeoGenomics compare to RadNet?

Do analysts prefer RDNT or NEO?

Does the media refer more to RDNT or NEO?

Which has better valuation & earnings, RDNT or NEO?

Is RDNT or NEO more profitable?

Which has more risk and volatility, RDNT or NEO?

Do insiders & institutionals believe in RDNT or NEO?

Summary

How does NeoGenomics compare to LifeStance Health Group?

Which has higher earnings & valuation, NEO or LFST?

Do insiders and institutionals hold more shares of NEO or LFST?

Do analysts prefer NEO or LFST?

Does the media refer more to NEO or LFST?

Which has more risk & volatility, NEO or LFST?

Is NEO or LFST more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEO vs. The Competition

NeoGenomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools